Clinical pipeline promises effective 2nd-generation COVID-19 vaccines Despite the small number of COVID-19 vaccines that have been granted emergency use authorizations by the U.S. Food and Drug Administration to date, many biopharmaceutical companies are continuing to push new vaccine candidates toward regulatory approval. The slow rollout of approved vaccines has created the need for second-generation products with the potential to accelerate the world's return to something approaching normalcy.Read More
Jaguar Gene Therapy launches, targeting rare genetic diseases Jaguar Gene Therapy has launched after being in stealth mode with the goal of accelerating the development, manufacturing, and commercialization of novel gene therapy treatments for patients with severe genetic diseases.Read More
Yokogawa leverages ICQ to bring bioreactors to U.S. Yokogawa Electric has entered into a partnership with Integrated Commissioning and Qualification Consultants (ICQ) in which ICQ will provide consulting and engineering services for the installation, maintenance, qualification, and support of Yokogawa's bioreactor systems and related products in the U.S.Read More
Simulations Plus, Univ. of Pittsburgh partner to evaluate large-molecule drugs Medical simulation software company Simulations Plus and the University of Pittsburgh Drug Discovery Institute have jointly received a phase I grant from the U.S. National Institutes of Health-funded Small Business Innovation Research grant to support their large-molecule safety collaboration.Read More
Oncolytics reports results of immuno-oncolytic virus with CAR T therapy Oncolytics Biotech is reporting new data from a preclinical study where pelareorep, its proprietary immuno-oncolytic virus and chimeric antigen receptor (CAR) T-cell combination therapy for solid tumors, vastly improved outcomes compared to the use of an oncolytic vesicular stomatitis virus to weaken tumors.Read More